Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report

被引：67
|
作者：
Schifitto, G
Peterson, DR
Zhong, J
Ni, H
Cruttenden, K
Gaugh, M
Gendelman, HE
Boska, M
Gelbard, H
机构：
[1] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Biostat, Rochester, NY 14642 USA
[3] Univ Rochester, Med Ctr, Dept Radiol, Rochester, NY 14642 USA
[4] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE USA
[5] Univ Nebraska, Med Ctr, Dept Radiol, Omaha, NE 68105 USA
来源：
NEUROLOGY | 2006年 / 66卷 / 06期
关键词：
D O I：
10.1212/01.wnl.0000204294.28189.03
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In vitro and animal model data demonstrate that valproic acid (VPA) can ameliorate HIV-associated neurotoxicity. The authors conducted a pilot 10-week placebo-controlled study of VPA 250 mg twice daily in 22 HIV-infected individuals with (n = 16) and without (n = 6) cognitive impairment. VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects.
引用
收藏
页码：919 / 921
页数：3
相关论文
共 50 条
  • [21] Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm
    Cysique, Lucette A.
    Brew, Bruce J.
    JOURNAL OF NEUROVIROLOGY, 2019, 25 (05) : 710 - 721
  • [22] Youth perinatal HIV-associated cognitive impairment: Associations with childhood trauma
    Phillips, N.
    Stein, D.
    Myer, L.
    Zar, H.
    Hoare, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 106 - 106
  • [23] Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment
    Underwood, Jonathan
    de Francesco, Davide
    Cole, James H.
    Caan, Matthan W. A.
    van Zoest, Rosan A.
    Schmand, Ben A.
    Sharp, David J.
    Sabin, Caroline A.
    Reiss, Peter
    Winston, Alan
    Reiss, P.
    Wit, F. W. N. M.
    Schouten, J.
    Kooij, K. W.
    van Zoest, R. A.
    Elsenga, B. C.
    Janssen, F. R.
    Heidenrijk, M.
    Zikkenheiner, W.
    van der Valk, M.
    Kootstra, N. A.
    Harskamp-Holwerda, A. M.
    Maurer, I
    Ruiz, M. M. Mangas
    Girigorie, A. F.
    Villaudy, J.
    Frankin, E.
    Pasternak, A.
    Berkhout, B.
    van der Kuyl, T.
    Portegies, P.
    Schmand, B. A.
    Geurtsen, G. J.
    ter Stege, J. A.
    Twennaar, M. Klein
    Majoie, C. B. L. M.
    Caan, M. W. A.
    Su, T.
    Weijer, K.
    Bisschop, P. H. L. T.
    Kalsbeek, A.
    Wezel, M.
    Visser, I
    Ruhe, H. G.
    Franceschi, C.
    Garagnani, P.
    Pirazzini, C.
    Capri, M.
    Dall'Olio, F.
    Chiricolo, M.
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (06):
  • [24] Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study
    Munoz-Moreno, Jose A.
    Prats, Anna
    Molto, Jose
    Garolera, Maite
    Perez-Alvarez, Nuria
    Diez-Quevedo, Crisanto
    Miranda, Cristina
    Fumaz, Carmina R.
    Ferrer, Maria J.
    Clotet, Bonaventura
    PLOS ONE, 2017, 12 (08):
  • [25] Vascular cognitive impairment and HIV-associated neurocognitive disorder: a new paradigm
    Lucette A. Cysique
    Bruce J. Brew
    Journal of NeuroVirology, 2019, 25 : 710 - 721
  • [26] A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
    Schifitto, G.
    Zhang, J.
    Evans, S. R.
    Sacktor, N.
    Simpson, D.
    Millar, L. L.
    Hung, V. L.
    Miller, E. N.
    Smith, E.
    Ellis, R. J.
    Valcour, V.
    Singer, E.
    Marra, C. M.
    Kolson, D.
    Weihe, J.
    Remmel, R.
    Katzenstein, D.
    Clifford, D. B.
    NEUROLOGY, 2007, 69 (13) : 1314 - 1321
  • [27] Magnetic resonance spectroscopic imaging measures metabolite changes during therapy for HIV-Associated cognitive impairment
    Sacktor, NC
    Pomper, MG
    Horska, A
    Barker, PB
    McArthur, JC
    NEUROLOGY, 2000, 54 (07) : A252 - A252
  • [28] Aging with HIV and HIV-associated neurocognitive impairment
    Bennett, Teresa
    Walmsley, Sharon
    Bendayan, Reina
    AIDS, 2025, 39 (03) : 215 - 228
  • [29] Benzodiazepine Use and HIV-Associated Neurocognitive Impairment: Which Comes First?
    Mantovani, Elisa
    Lugoboni, Fabio
    Federico, Angela
    Zipeto, Donato
    Tamburin, Stefano
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (04) : E26 - E27
  • [30] Can antiretroviral therapy prevent HIV-associated cognitive disorders?
    Winston, Alan
    Vera, Jaime H.
    CURRENT OPINION IN HIV AND AIDS, 2014, 9 (01) : 11 - 16
12345